Yahoo Finance Names Novo Nordisk as 2023 Company of the Year\n\nNovo Nordisk (NVO) has been named the 2023 Company of the Year by Yahoo Finance. The pharmaceutical firm, known for its weight-loss drugs Ozempic and Wegovy, has seen a 40% increase in its stock value this year. This has sparked speculation about potential impacts on other industries, such as restaurants and food companies.\n\nTD Cowen Managing Director Andrew Charles Discusses Outlook for GLP-1s\n\nTD Cowen Managing Director Andrew Charles recently joined Yahoo Finance to discuss the company’s outlook for GLP-1s, including Novo Nordisk’s weight-loss drugs. According to Charles, the company’s 2030 outlook includes 14.3 million people in the United States taking GLP-1s, a 30% reduction in calories by users, and a 0.07% decrease in overall U.S. Population calorie consumption. Charles notes that this may not have a significant impact on the market.\n\nNovo Nordisk’s Unique Corporate Structure\n\nOne interesting aspect of Novo Nordisk that many investors may not be aware of is its unique corporate structure. The company’s voting power is owned by the non-profit Novo Nordisk Foundation, which holds all of the company’s Class A shares. This structure has contributed to the company’s success and stability.\n\nEli Lilly Stock Drops After Study on Weight-Loss Drug\n\nIn related news, Eli Lilly’s stock saw a decline after a study showed that patients who stopped taking their weight-loss drug regained weight over a year. \n\nNovo Nordisk has been named the 2023 Company of the Year by Yahoo Finance.

IN8bio Presents Promising Data for DeltEx DRI Immunotherapy at SNO Annual Meeting\n\nIN8bio, Inc. (Nasdaq:INAB) has recently presented promising data at the Society for Neuro-Oncology (SNO) 28th Annual Meeting in Vancouver, British Columbia. The data, which was presented on November 17, 2023, demonstrates the potential of IN8bio's DeltEx Drug Resistant Immunotherapy (DRI) to treat patients with newly diagnosed glioblastoma (GBM).\n\nThe Phase 1 trial, which assesses the safety and preliminary efficacy of adding DeltEx DRI gamma-delta T cells to standard-of-care maintenance therapy, has shown promising results. Ten patients have been treated with INB-200, with most exceeding the expected progression-free survival (PFS) based on their age and tumor status. Additionally, one patient with an IDH-mutant glioma remains alive and progression-free at 28.5+ months, surpassing the median PFS of 11.1 months for IDH-mutant patients in the control arm of a clinical trial.\n\nThe safety data from the ongoing study is also encouraging, with no treatment-related serious adverse events (SAEs), dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), infusion reactions, or immune effector cell-associated neurotoxicity syndrome (ICANS) reported in any cohort. The most common treatment-emergent adverse events (TEAEs) were mostly Grade 1-2 toxicities consisting of white blood cell and platelet count decreases, nausea, and fatigue.\n\nIN8bio's Chief Medical Officer, Trishna Goswami, MD, expressed excitement about the results and the potential for improving treatment outcomes for GBM patients and potentially other solid tumor cancers. The company plans to continue enrolling patients in the trial, with completion of enrollment in Cohort 3 expected in 2023 and long-term follow-up data to be presented at medical meetings in 2024.\n\n